Cost analyses of community-acquired pneumonia from the hospital perspective

Chest

Volumn 128, Issue 4, 2005, Pages 2238-2246

  Bauer, Torsten Thomas ^a,e   Welte, Tobias ^b   Ernen, Carolin ^c   Schlosser, Barbara Monika ^a   Thate Waschke, Inga ^d   De Zeeuw, Justus ^a   Schultze Werninghaus, Gerhard ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c Institute of Empirical Health Economics   (Germany)

^d BAYER AG   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Community acquired pneumonia; Cost; Length of hospital stay; Moxifloxacin

Indexed keywords

MOXIFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COST BENEFIT ANALYSIS; DRUG EFFICACY; FEMALE; GERMANY; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 27144503793     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2238     Document Type: Article

References (23)

1. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20:820-837
2. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: incidence, etiology, and impact. Am J Med 1985; 78:32-37
3. Major respiratory diseases: pneumonia. In: Loddenkemper R, Gibson GJ, Sibille Y, eds. European lung white book: the first comprehensive survey on respiratory health in Europe. Sheffield, UK: European Respiratory Society and European Lung Foundation, 2003; 55-64
4. Konietzko N, Fabel H. Weißbuch lunge. Stuttgart, Germany: Thieme, 2000
5. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283:749-755
6. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003; 124:526-535
7. Bartolomé M, Almirall J, Morera J, et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J 2004; 23:610-616
8. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250
9. Drummond MF, Stoddart GL, Torrance GW. Critical assessment of economic evaluation: methods for the economic evaluation of health care programs. Oxford, UK: Oxford University Press, 1987; 18-32
10. Colice GL, Morley MA, Asche C, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004; 125:2140-2145
11. Milo LA, Smucker W, Logue E, et al. Shoot, ready, aim: pneumonia care quality and costs in a community hospital. Am J Med Qual 2003; 18:214-219
12. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am J Med 2000; 109:378-385
13. Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 2003; 124:2148-2155
14. Woolhandler S, Campbell T, Himmelstein DU. Costs of health care administration in the United States and Canada. N Engl J Med 2003; 349:768-775
15. Brown PD. Adherence to guidelines for community-acquired pneumonia: does it decrease cost of care? Pharmacoeconomics 2004; 22:413-420
16. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746-1754
17. Van Zanten AR, Engelfriet PM, van Dillen K, et al. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 2003; 7:R184-R190
18. Lode H, Grossman C, Choudhri S, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003; 97:1134-1142
19. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111:367-374
20. Oosterheert JJ, Bonten MJ, Buskens E, et al. Algorithm to determine cost savings of targeting antimicrobial therapy based on results of rapid diagnostic testing. J Clin Microbiol 2003; 41:4708-4713
21. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-395
22. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21:135-143
23. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342:1878-1886